Abstract

Introduction

A reduction in platelet count in critically ill patients is a marker of severity of the clinical condition. However, whether this association holds true in acute kidney injury (AKI) is unknown. We analyzed the association between platelet reduction in patients with AKI and major adverse kidney events (MAKE).

Methods

In this retrospective cohort, we included AKI patients at the Hospital Civil of Guadalajara, in Jalisco, Mexico. Patients were divided according to whether their platelet count fell >21% during the first 10 days. Our objectives were to analyze the associations between a platelet reduction >21% and MAKE at 10 days (MAKE10) or at 30-90 days (MAKE30-90) and death.

Results

From 2017 to 2023, 400 AKI patients were included, 134 of whom had a > 21% reduction in platelet count. The mean age was 54 years, 60% were male, and 44% had sepsis. The mean baseline platelet count was 194 x 103 cells/µL, and 65% of the KDIGO3 patients met these criteria. Those who underwent hemodialysis (HD) had lower platelet counts. After multiple adjustments, a platelet reduction >21% was associated with MAKE10 (OR 4.2, CI 2.1-8.5) but not with MAKE30-90. The mortality risk increased 3-fold (OR 2.9, CI 1.1-7.7, p = 0.02) with a greater decrease in the platelets (<90 x 103 cells/µL). As the platelets decreased, the incidence of MAKE was more likely to increase. These associations lost significance when accounting for starting HD.

Conclusion

In our retrospective cohort of patients with AKI, a > 21% reduction in platelet count was associated with MAKE. Our results are useful for generating hypotheses and motivating us to continue studying this association with a more robust design.

Details

Title
Decrease in platelet count in patients with AKI and its association with major adverse kidney events
Author
Medina-González, Ramón 1   VIAFID ORCID Logo  ; Zaragoza, Jose J 2   VIAFID ORCID Logo  ; Hernández-Barajas, Eduardo M 3 ; Juarez Correa-de Leon 3 ; Rolando Claure-Del Granado 4 ; Vazquez-Rangel, Armando 5 ; Pineda-Segura, Liliana M 6 ; Franco-Garcia, Martha K 6 ; Chávez-Alonso, Gael 6 ; Gómez-Fregoso, Juan A 1 ; Rodríguez-García, Francisco G 1 ; Navarro-Blackaller, Guillermo 3   VIAFID ORCID Logo  ; Alcantar-Vallin, Luz 3   VIAFID ORCID Logo  ; Alejandro Martínez Gallardo-González 3 ; Abundis-Mora, Gabriela J 1 ; García-García, Guillermo 6   VIAFID ORCID Logo  ; Chávez-Iñiguez, Jonathan S 3   VIAFID ORCID Logo 

 Nephrology Service, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico 
 Intensive Care Unit, Hospital H + Queretaro, Mexico 
 Nephrology Service, Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Jalisco, Mexico; University of Guadalajara Health Sciences Center, Guadalajara, Jalisco, Mexico 
 Division of Nephrology, Hospital Obrero No 2 – CNS. IIBISMED, Facultad de Medicina, Universidad Mayor de San Simon, Cochabamba, Bolivia 
 Department of Nephrology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico 
 University of Guadalajara Health Sciences Center, Guadalajara, Jalisco, Mexico 
Publication year
2024
Publication date
Dec 2024
Publisher
Taylor & Francis Ltd.
ISSN
0886022X
e-ISSN
15256049
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3073446913
Copyright
© 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This work is licensed under the Creative Commons  Attribution – Non-Commercial License http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.